Physician profile
Sarah E Voss
NPI 1407130842
$1,207.94
in general payments reported to CMS, 2019-2025
13 companies · $15.65 in 2025
The $15.65 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $24.35 · 2022: $208 · 2023: $379 · 2024: $582 · 2025: $15.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $976.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $976.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $390.85 | 2022-2024 | Rybelsus, Ozempic, Wegovy |
| Abbott Laboratories | $178.24 | 2021-2024 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $144.66 | 2023 | Jardiance, Tradjenta |
| Csl Behring | $104.62 | 2024 | Kcentra |
| Astrazeneca Pharmaceuticals LP | $101.92 | 2024 | Breztri |
| Abbvie INC. | $67.35 | 2023-2024 | |
| Amgen INC. | $54.12 | 2024 | Otezla, Repatha, Evenity |
| Merck Sharp & Dohme LLC | $48.19 | 2023 | Gardasil 9, M-M-R II, Vaxelis |
| Astellas Pharma US INC | $42.16 | 2023-2024 | Veozah |
| Xeris Pharmaceuticals, INC. | $24.35 | 2023 | Gvoke Hypopen |
| Lilly USA, LLC | $20.26 | 2023 | Emgality, Jardiance |
| Glaxosmithkline, LLC. | $15.65 | 2025 | Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $15.57 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Voss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.